首页 > 研究领域 > Cancer
产品编号 产品名称 CAS No.
DC7342 Foretinib(XL880)

Foretinib (GSK1363089; XL880; EXEL-2880; GSK089) is an ATP-competitive inhibitor of HGFR and VEGFR, mostly for Met and KDR with IC50 of 0.4 nM and 0.9 nM. Less potent against Ron, Flt-1/3/4, Kit, PDGFRα/β and Tie-2, and little activity to FGFR1 and EGFR.

849217-64-7
DC7486 PX-478 2HCL

PX-478 is an inhibitor of HIF-1a with an IC50 of 20-30μM enhances radiosensitivity of prostate carcinoma cells.

685898-44-6
DC7506 Sotrastaurin

Sotrastaurin(AEB-071) is a potent and selective pan-PKC inhibitor, mostly for PKCθ with Ki of 0.22 nM; inactive to PKCζ.

425637-18-9
DC7544 CUDC-101

CUDC-101 is a potent multi-targeted inhibitor against HDAC, EGFR and HER2 with IC50 of 4.4 nM, 2.4 nM, and 15.7 nM, and inhibits class I/II HDACs, but not class III, Sir-type HDACs. Phase 1.

1012054-59-9
DC7868 AS703026(Pimasertib)

1236699-92-5
DC8116 Tosedostat (CHR2797)

CHR-2797 is an aminopeptidase inhibitor, with IC50 values of 100 nM for LAP3 (LAP), 150 nM for PSAP (PuSA) and 220 nM for CD13 (Aminopeptidase N).

238750-77-1
DC8630 Ralimetinib 2MsOH(LY2228820)

LY2228820 is a novel and potent p38MAPK inhibitor (the IC50 for p38αMAPK and p38βMAPK were 7 nM and 3 nM, respectively).

862507-23-1
DC8791 Sorafenib free base (BAY-43-9006)

Sorafenib(BAY 43-9006) is a potent inhibitor of Raf-1 with IC50 values of 6 nM, 22 nM and 90 nM for Raf-1, B-Raf, and VEGFR2 respectively, BAY 43-9006 suppresses both wild-type and V599E mutant BRAF activity in vitro.

284461-73-0
DC8940 Raltitrexed

Raltitrexed(ZD1694), an inhibitor of thymidylate synthase, is an antimetabolite drug used in cancer chemotherapy.

112887-68-0
DC9013 Cyclophosphamide

Cyclophosphamide is a synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities.

50-18-0
DC9095 Carboplatin

Carboplatin is a chemotherapy drug by binding to DNA and interfering with the cell's repair mechanism.

41575-94-4
DC9298 thiotepa

N,N’N’-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group.

52-24-4
DC9679 BAY1217389

BAY1217389 is an orally bioavailable, selective inhibitor of the serine/threonine kinase monopolar spindle 1 (Mps1, TTK), with potential antineoplastic activity.

1554458-53-5
DC9879 AZD8835

AZD8835 ia a novel mixed inhibitor of PI3Kα and PI3Kδ with IC50 of 6.2 nM and 5.7 nM, respectively, also with selectivity against PI3Kβ (IC50=431 nM) and PI3Kγ (IC50=90 nM).

1620576-64-8
DCAPI1512 Lapatinib

Lapatinib

231277-92-2
DCAPI1525 5-Azacytidine

5-Azacytidine is a potent growth inhibitor and a cytotoxic agent. 5-Azacytidine acts as a demethylating agent by inhibiting DNA methyltransferase (Dnmt), forming covalent adducts with cellular DNMT1 depleting enzyme activity. 5-Azacytidine also improves t

320-67-2
第 18 页 / 共 18 页第一页上一页下一页最末页转到